Seaport Therapeutics
Seaport Therapeutics is seeking a senior clinical development leader to advance global neuropsychiatric programs and drive strategic progress of the company’s pipeline. The role requires deep neuroscience expertise and experience with regulatory milestones and submissions, including IND/NDA interactions. The position is based in Boston’s Seaport area with a strong preference for being onsite four days per week.
Seaport Therapeutics is a biotechnology company developing novel neuropsychiatric medicines. The company applies its Glyph platform to advance potentially best-in-class therapeutics designed to improve efficacy and tolerability for patients with depression, anxiety, and other neuropsychiatric disorders.
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
2 weeks ago
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 5, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Seaport Therapeutics.
Senior Manager, Regulatory Strategy
Beeline Medicines
Regulatory affairs Manager
Integrated Resources INC
Clinical Development, Program Lead
altoneuroscience
Associate Director, Regulatory Affairs
AbCellera
Medical Director, Clinical Research Cardiovascular
Cytokinetics
Regulatory affairs Manager
Integrated Resources INC